MarketsandMarkets Conferences Blogs
For as long as medicine has existed, cancers have ravaged humanity. The search for an eventual cure has been a tremendous & tireless pursuit, selflessly undertaken by doctors, researchers, scientists & the entire healthcare community. With each passing year and the availability of sophisticated technologies, their efforts continue to go from strength to strength, expanding […]
Héctor’s work has always focused on understanding the molecular pathophysiological mechanisms leading to autoimmunity and cancer development, investigating mechanism of action of newly developed molecules to treat such diseases. He started his career in 2006 when he moved to UT Southwestern Medical Center in Dallas (EEUU), to carry out this thesis in developing novel therapeutic […]
Philadelphia, USA August 10, 2019 – MarketsandMarkets recently interviewed William Williams, President, CEO BriaCell Corporation regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. The major advance […]
Philadelphia, USA August 09, 2019 – MarketsandMarkets recently interviewed Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Emmanuel Normant is vice president of preclinical sciences at TG Therapeutics, a clinical-stage biotech company focused on hematologic cancers and […]
Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab […]
According to a statement by the VP of Roche technical development bioprocessing, Wolfgang Kuhne said that the older processes used to produce monoclonal antibodies like Herceptin and Avastin are not sufficient to produce complex and advanced pharmaceuticals. A bioprocess international European summit was held in Vienna, Austria during which delegates were told that making candidates […]
